NASDAQ:POAI

Predictive Oncology Stock Forecast, Price & News

$1.25
-0.26 (-17.22 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.25
$1.52
50-Day Range
$0.84
$1.58
52-Week Range
$0.63
$2.30
Volume4.52 million shs
Average Volume1.63 million shs
Market Capitalization$62.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
30 days | 90 days | 365 days | Advanced Chart
Receive POAI News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.


Predictive Oncology logo

About Predictive Oncology

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

987th out of 2,099 stocks

Surgical Appliances & Supplies Industry

19th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Predictive Oncology (NASDAQ:POAI) Frequently Asked Questions

Is Predictive Oncology a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Predictive Oncology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Predictive Oncology stock.
View analyst ratings for Predictive Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Predictive Oncology?

Wall Street analysts have given Predictive Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Predictive Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Predictive Oncology?

Predictive Oncology saw a decrease in short interest in the month of May. As of May 28th, there was short interest totaling 3,500,000 shares, a decrease of 20.8% from the May 13th total of 4,420,000 shares. Based on an average daily volume of 2,320,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 7.7% of the shares of the company are short sold.
View Predictive Oncology's Short Interest
.

When is Predictive Oncology's next earnings date?

Predictive Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Predictive Oncology
.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings data on Wednesday, May, 12th. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The medical instruments supplier earned $0.28 million during the quarter. Predictive Oncology had a negative trailing twelve-month return on equity of 79.64% and a negative net margin of 2,039.09%.
View Predictive Oncology's earnings history
.

How has Predictive Oncology's stock been impacted by COVID-19?

Predictive Oncology's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, POAI stock has decreased by 41.6% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for POAI?

1 Wall Street analysts have issued 12-month target prices for Predictive Oncology's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Predictive Oncology's stock price to reach $3.00 in the next year. This suggests a possible upside of 140.0% from the stock's current price.
View analysts' price targets for Predictive Oncology
or view top-rated stocks among Wall Street analysts.

Who are Predictive Oncology's key executives?

Predictive Oncology's management team includes the following people:
  • Mr. J. Melville Engle, Chairman & CEO (Age 71, Pay $3k)
  • Mr. Robert L. Myers, CFO & Sec. (Age 66, Pay $327.84k)
  • Mr. Kevin Hungerford, VP of Sales & Marketing

Who are some of Predictive Oncology's key competitors?

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Blockchain (RIOT), AcelRx Pharmaceuticals (ACRX), The Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE).

What is Predictive Oncology's stock symbol?

Predictive Oncology trades on the NASDAQ under the ticker symbol "POAI."

Who are Predictive Oncology's major shareholders?

Predictive Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.12%), Renaissance Technologies LLC (1.19%), Goldman Sachs Group Inc. (0.33%), Geode Capital Management LLC (0.28%), Virtu Financial LLC (0.17%) and Northern Trust Corp (0.14%). Company insiders that own Predictive Oncology stock include Carl I Schwartz and Richard L Gabriel.
View institutional ownership trends for Predictive Oncology
.

Which major investors are buying Predictive Oncology stock?

POAI stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Geode Capital Management LLC, Virtu Financial LLC, Northern Trust Corp, Maryland Capital Management, and Bank of New York Mellon Corp.
View insider buying and selling activity for Predictive Oncology
or or view top insider-buying stocks.

How do I buy shares of Predictive Oncology?

Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Predictive Oncology's stock price today?

One share of POAI stock can currently be purchased for approximately $1.25.

How much money does Predictive Oncology make?

Predictive Oncology has a market capitalization of $62.28 million and generates $1.25 million in revenue each year.

How many employees does Predictive Oncology have?

Predictive Oncology employs 22 workers across the globe.

What is Predictive Oncology's official website?

The official website for Predictive Oncology is www.precisiontherapeutics.com.

Where are Predictive Oncology's headquarters?

Predictive Oncology is headquartered at 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121.

How can I contact Predictive Oncology?

Predictive Oncology's mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier can be reached via phone at 651-389-4800 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.